Thermo Fisher Scientific Inc.: Form 10-Q for the period ended Sep 28, 2024
Filed with the SEC on Nov 1, 2024 and accepted by EDGAR at Nov 1, 2024, 11:36 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-09-28. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-06-30 to 2024-09-28 | $10.60bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2024-01-01 to 2024-09-28 | $31.48bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2024-06-30 to 2024-09-28 | $346.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2024-01-01 to 2024-09-28 | $1.02bn | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-06-30 to 2024-09-28 | $2.10bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2024-01-01 to 2024-09-28 | $6.39bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-06-30 to 2024-09-28 | $1.84bn | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-01-01 to 2024-09-28 | $5.32bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-06-30 to 2024-09-28 | $356.0m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months2024-01-01 to 2024-09-28 | $1.07bn | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2024-06-30 to 2024-09-28 | $99.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2024-01-01 to 2024-09-28 | $507.0m | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months2024-06-30 to 2024-09-28 | $4.25 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-01-01 to 2024-09-28 | $11.75 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-06-30 to 2024-09-28 | $4.26 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-01-01 to 2024-09-28 | $11.79 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-06-30 to 2024-09-28 | 384,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-01-01 to 2024-09-28 | 383,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-01-01 to 2024-09-28 | $5.38bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2024-01-01 to 2024-09-28 | $920.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2024-01-01 to 2024-09-28 | $434.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months2024-01-01 to 2024-09-28 | $3.00bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2024-09-28 | $4.64bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-09-28 | $23.78bn | us-gaap:AssetsCurrent |
| Total assets | At period end2024-09-28 | $100.36bn | us-gaap:Assets |
| Current liabilities | At period end2024-09-28 | $14.60bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2024-09-28 | $35.11bn | us-gaap:LongTermDebt |
| Current portion of debt | At period end2024-09-28 | $4.12bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2024-09-28 | $48.99bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2024-09-28 | 382,500,265 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000097745-24-000046. Last ingested by Listed: Nov 6, 2026, 03:40 ET. Listed shows no prices and gives no investment advice.